Startup entity
market-trends is the sole category represented across all 1 tracked stories. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. At 6, the average consequence score sits below the same-window beat average of 6.5.
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. At 6, the average consequence score sits below the same-window beat average of 6.5. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. JNJ-2113 appears in 1 tracked Startup story from February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JNJ-2113. Shared-story counts are live from our verified record — not editorial picks.
Institutional Exit
SEC filings reveal a $170 million position liquidation by a major fund.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
JNJ-2113 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
